Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021

View ORCID ProfileMegha L. Mehrotra, Esther Lim, Katherine Lamba, Amanda Kamali, Kristina W. Lai, Erika Meza, Irvin Szeto, Peter Robinson, Cheng-ting Tsai, David Gebhart, Noemi Fonseca, Andrew B. Martin, Catherine Ley, Steve Scherf, James Watt, David Seftel, Julie Parsonnet, Seema Jain
doi: https://doi.org/10.1101/2021.12.09.21267565
Megha L. Mehrotra
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Megha L. Mehrotra
  • For correspondence: Megha.mehrotra@cdph.ca.gov
Esther Lim
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Lamba
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda Kamali
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristina W. Lai
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erika Meza
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irvin Szeto
2Stanford University, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Robinson
3Enable Biosciences, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng-ting Tsai
3Enable Biosciences, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Gebhart
3Enable Biosciences, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noemi Fonseca
3Enable Biosciences, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew B. Martin
2Stanford University, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Ley
2Stanford University, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steve Scherf
4Gauss Surgical, Menlo Park, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Watt
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Seftel
3Enable Biosciences, South San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parsonnet
2Stanford University, Palo Alto, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seema Jain
1California Department of Public Health, Richmond, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Importance Understanding how SARS-CoV-2 seroprevalence varies regionally across California is critical to the public health response to the pandemic.

Objective To estimate how many Californians have antibodies against SARS-CoV-2 from prior infection or vaccination.

Design Wave 1 of CalScope: a repeated cross-sectional serosurvey of adults and children enrolled between April 20, 2021 and June 16, 2021.

Setting A population-based random sample of households in seven counties in California (Alameda, El Dorado, Kern, Los Angeles, Monterey, San Diego, and Shasta) were invited to complete an at-home SARS-CoV-2 antibody test and survey instrument.

Participants Invitations were sent to 200,000 randomly selected households in the seven counties. From each household, 1 adult (18 years and older) and 1 child (aged 6 months to 17 years) could enroll in the study. There were no exclusion criteria.

Main Outcome(s) and Measures All specimens were tested for antibodies against the nucleocapsid and spike proteins of SARS-CoV-2. The primary outcome was serostatus category, which was determined based on antibody test results and self-reported vaccination status: seronegative, antibodies from infection only, antibodies from infection and vaccination, and antibodies from vaccination alone. We used inverse probability of selection weights and iterative proportional fitting to account for non-response.

Results 11,161 households enrolled in wave 1 of CalScope, with 7,483 adults and 1,375 children completing antibody testing. As of June 2021, 27% (95%CI [23%, 31%]) of adults and 30% (95%CI [24%, 36%]) of children had evidence of prior SARS-CoV-2 infection; 33% (95%CI [28%, 37%]) of adults and 57% (95%CI [48%, 66%]) of children were seronegative. Serostatus varied regionally. Californians 65 years or older were most likely to have antibodies from vaccine alone (59%; 95%CI [48%, 69%]) and children between 5-11 years old were most likely to have antibodies from prior infection alone (36%; 95%CI [21%, 52%]).

Conclusions and Relevance As of June 2021, a third of adults in California and most children under 18 remained seronegative. Seroprevalence varied regionally and by demographic group, suggesting that some regions or populations might remain more vulnerable to subsequent surges than others.

Question What is the prevalence of vaccine and infection derived antibodies against SARS-CoV-2 in adults and children in California?

Findings In this population-based serosurvey that included 11,161 households, as of June 2021, 33% of adults and 57% of children were seronegative; 18% of adults and 26% of children had antibodies from infection alone; 9% of adults and 5% of children had antibodies from both infection and vaccination; and 41% of adults and 13% of children had antibodies from vaccination alone.

Meaning Serostatus varied considerably across geographic regions, suggesting that certain areas might be at increased risk for future COVID-19 surges.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

the Centers for Disease Control

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Committee for Protection of Human Subjects of the State of California waived ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021
Megha L. Mehrotra, Esther Lim, Katherine Lamba, Amanda Kamali, Kristina W. Lai, Erika Meza, Irvin Szeto, Peter Robinson, Cheng-ting Tsai, David Gebhart, Noemi Fonseca, Andrew B. Martin, Catherine Ley, Steve Scherf, James Watt, David Seftel, Julie Parsonnet, Seema Jain
medRxiv 2021.12.09.21267565; doi: https://doi.org/10.1101/2021.12.09.21267565
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021
Megha L. Mehrotra, Esther Lim, Katherine Lamba, Amanda Kamali, Kristina W. Lai, Erika Meza, Irvin Szeto, Peter Robinson, Cheng-ting Tsai, David Gebhart, Noemi Fonseca, Andrew B. Martin, Catherine Ley, Steve Scherf, James Watt, David Seftel, Julie Parsonnet, Seema Jain
medRxiv 2021.12.09.21267565; doi: https://doi.org/10.1101/2021.12.09.21267565

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8793)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1864)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (395)
  • Infectious Diseases (except HIV/AIDS) (10574)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1760)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3991)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)